Label

How We Work

Grant

Back

Print

Vaxxas Pty Ltd


November 2016
to fund the pre-clinical development of Nanopatch microarray patch technology for the delivery of measles rubella vaccine, with the aim of overcoming gaps in measles rubella vaccine coverage particularly in low and middle-income countries
$4,479,552
43
Delivery of Solutions to Improve Global Health, Discovery and Translational Sciences, Pneumonia
Global Development|Global Health
Brisbane, Queensland

Visit Our Blog